Cannabinoids Are Test Case For US FDA Advisors’ ‘Predicted Pharmacological Activity’ Discussion
Wide Variety Of Additional Topics On Tap In Science Board’s Online Meeting
Executive Summary
Busy agenda of disparate topics in one-day meeting likely valuable for informing FDA on safety of hemp ingredients but not for moving toward a regulatory pathway for the ingredients' lawful use in supplements and food.
You may also be interested in...
Solving US Hemp Regulatory Problem Will Take Wider View Of FDA Rule – AHPA’s McGuffin
FDA, along with supplement and food industries, have looked to Congress to authorizing agency to waive exclusion rule for hemp ingredients. Instead, Michael McGuffin recommends amending DSHEA to clarify that the same ingredients at different concentrations can be allowed in supplements and drugs.
Science Board Meeting Could Launch US Toward Lawful Hemp Use, Or Extend Market Limbo
Questions FDA is asking advisors and the public could generate answers propelling it toward determining whether hemp use in supplements should be lawful with a waiver of its prohibition against using ingredients studied or approved as a drug; or, the answers could stop the FDA in its feet.
It’s Official: US Enforcement Discretion For NAC In Supplements, And Regulatory Options For FDA
Draft guidance states enforcement discretion allowing sales of N-acetyl-L-cysteine supplements which FDA in 2020 ordered firms to halt selling due to its use as a drug ingredient. However, NAC supplements, as they have remained since 2020, were available to US consumers when draft was published.